Taysha Gene Therapies, Inc. Research and Development Expense
Taysha Gene Therapies, Inc. (TSHA) reported Research and Development Expense of $38.64 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-11
- Taysha Gene Therapies, Inc. research and development expense for the quarter ending 2026-06-30 was $38.64M, a 91.83% increase year-over-year.
- Taysha Gene Therapies, Inc. research and development expense for the quarter ending 2026-03-31 was $33.81M, a 117.21% increase year-over-year.
- Taysha Gene Therapies, Inc. research and development expense for the quarter ending 2025-12-31 was $24.95M, a 62.82% increase year-over-year.
- Taysha Gene Therapies, Inc. research and development expense for the quarter ending 2025-09-30 was $25.75M, a 72.25% increase year-over-year.
- Taysha Gene Therapies, Inc. research and development expense for fiscal 2025 was $86.40M, a 30.91% increase from fiscal 2024.
- Taysha Gene Therapies, Inc. research and development expense for fiscal 2024 was $66.00M, a 16.24% increase from fiscal 2023.
- Taysha Gene Therapies, Inc. research and development expense for fiscal 2023 was $56.78M, a 37.72% decline from fiscal 2022.
- Taysha Gene Therapies, Inc. research and development expense for fiscal 2022 was $91.17M, a 30.90% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $38.64M 10-Q · filed 2026-08-11 | $72.44M 10-Q · filed 2026-08-11 | $97.40M derived: sum of 3 quarters · filed 2026-08-11 | $123.14M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2026-03-31 | $33.81M 10-Q · filed 2026-05-06 | $58.76M derived: sum of 2 quarters · filed 2026-05-06 | $84.51M derived: sum of 3 quarters · filed 2026-05-06 | $104.65M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-12-31 | $24.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $50.70M derived: sum of 2 quarters · filed 2026-03-19 | $70.84M derived: sum of 3 quarters · filed 2026-08-11 | $86.40M 10-K · filed 2026-03-19 | |||
| 2025-09-30 | $25.75M 10-Q · filed 2025-11-04 | $45.89M derived: sum of 2 quarters · filed 2026-08-11 | $61.45M 10-Q · filed 2025-11-04 | $76.78M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-06-30 | $20.14M 10-Q · filed 2026-08-11 | $35.71M 10-Q · filed 2026-08-11 | $51.03M derived: sum of 3 quarters · filed 2026-08-11 | $65.98M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-03-31 | $15.56M 10-Q · filed 2026-05-06 | $30.89M derived: sum of 2 quarters · filed 2026-05-06 | $45.84M derived: sum of 3 quarters · filed 2026-05-06 | $60.91M derived: sum of 4 quarters · filed 2026-05-06 | |||
| 2024-12-31 | $15.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $30.27M derived: sum of 2 quarters · filed 2026-03-19 | $45.34M derived: sum of 3 quarters · filed 2026-03-19 | $66.00M 10-K · filed 2026-03-19 | |||
| 2024-09-30 | $14.95M 10-Q · filed 2025-11-04 | $30.02M derived: sum of 2 quarters · filed 2025-11-04 | $50.68M 10-Q · filed 2025-11-04 | $63.36M derived: sum of 4 quarters · filed 2025-11-04 | |||
| 2024-06-30 | $15.07M 10-Q · filed 2025-08-12 | $35.73M 10-Q · filed 2025-08-12 | $48.41M derived: sum of 3 quarters · filed 2025-08-12 | $60.20M derived: sum of 4 quarters · filed 2025-08-12 | |||
| 2024-03-31 | $20.66M 10-Q · filed 2025-05-15 | $33.34M derived: sum of 2 quarters · filed 2025-05-15 | $45.13M derived: sum of 3 quarters · filed 2025-05-15 | $64.92M derived: sum of 4 quarters · filed 2025-05-15 | |||
| 2023-12-31 | $12.68M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $24.47M derived: sum of 2 quarters · filed 2025-02-26 | $44.26M derived: sum of 3 quarters · filed 2025-02-26 | $56.78M 10-K · filed 2025-02-26 | |||
| 2023-09-30 | $11.79M 10-Q · filed 2024-11-13 | $31.58M derived: sum of 2 quarters · filed 2024-11-13 | $44.10M 10-Q · filed 2024-11-13 | $56.80M derived: sum of 4 quarters · filed 2024-11-13 | |||
| 2023-06-30 | $19.79M 10-Q · filed 2024-08-12 | $32.30M 10-Q · filed 2024-08-12 | $45.01M derived: sum of 3 quarters · filed 2024-08-12 | $61.79M derived: sum of 4 quarters · filed 2024-08-12 | |||
| 2023-03-31 | $12.51M 10-Q · filed 2024-05-14 | $25.22M derived: sum of 2 quarters · filed 2024-05-14 | $41.99M derived: sum of 3 quarters · filed 2024-05-14 | $65.50M derived: sum of 4 quarters · filed 2024-05-14 | |||
| 2022-12-31 | $12.71M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $29.48M derived: sum of 2 quarters · filed 2024-03-19 | $52.99M derived: sum of 3 quarters · filed 2024-03-19 | $91.17M 10-K · filed 2024-03-19 | |||
| 2022-09-30 | $16.77M 10-Q · filed 2023-11-14 | $16.39M 10-Q · filed 2022-11-08 | $40.28M derived: sum of 2 quarters · filed 2023-11-14 | $78.46M 10-Q · filed 2023-11-14 | $77.31M 10-Q · filed 2022-11-08 | $116.38M derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | $23.51M 10-Q · filed 2023-08-14 | $23.12M 10-Q · filed 2022-08-11 | $61.69M 10-Q · filed 2023-08-14 | $60.92M 10-Q · filed 2022-08-11 | $99.61M derived: sum of 3 quarters · filed 2023-08-14 | $139.13M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $38.18M 10-Q · filed 2023-05-11 | $37.80M 10-Q · filed 2022-05-16 | $76.10M derived: sum of 2 quarters · filed 2023-05-11 | $115.63M derived: sum of 3 quarters · filed 2023-05-11 | $146.27M derived: sum of 4 quarters · filed 2023-05-11 | ||
| 2021-12-31 | $37.92M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $77.45M derived: sum of 2 quarters · filed 2023-03-28 | $108.09M derived: sum of 3 quarters · filed 2023-03-28 | $131.94M 10-K · filed 2023-03-28 | |||
| 2021-09-30 | $39.53M 10-Q · filed 2022-11-08 | $70.17M derived: sum of 2 quarters · filed 2022-11-08 | $94.03M 10-Q · filed 2022-11-08 | $106.28M derived: sum of 4 quarters · filed 2022-11-08 | |||
| 2021-06-30 | $30.64M 10-Q · filed 2022-08-11 | $54.50M 10-Q · filed 2022-08-11 | $66.76M derived: sum of 3 quarters · filed 2022-08-11 | $77.81M derived: sum of 4 quarters · filed 2022-08-11 | |||
| 2021-03-31 | $23.85M 10-Q · filed 2022-05-16 | $36.11M derived: sum of 2 quarters · filed 2022-05-16 | $47.17M derived: sum of 3 quarters · filed 2022-05-16 | $50.23M derived: sum of 4 quarters · filed 2022-05-16 | |||
| 2020-12-31 | $12.26M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $23.32M derived: sum of 2 quarters · filed 2022-03-31 | $26.38M derived: sum of 3 quarters · filed 2022-03-31 | $31.89M 10-K · filed 2022-03-31 | |||
| 2020-09-30 | $11.06M 10-Q · filed 2021-11-10 | $14.12M derived: sum of 2 quarters · filed 2021-11-10 | $19.63M 10-Q · filed 2021-11-10 | $20.62M derived: sum of 4 quarters · filed 2021-11-10 | |||
| 2020-06-30 | $3.06M 10-Q · filed 2021-08-16 | $8.58M 10-Q · filed 2021-08-16 | $9.56M derived: sum of 3 quarters · filed 2021-08-16 | ||||
| 2020-03-31 | $5.51M 10-Q · filed 2021-05-11 | $6.50M derived: sum of 2 quarters · filed 2021-05-11 | |||||
| 2019-12-31 | $987.00K 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |